Sirnaomics Ltd.
Research Sirnaomics Ltd. (V5Z) on Bullrun: market cap EUR 50.38M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerV5Z
- ExchangeF
- CountryHong Kong
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 50.38M
- Financial periodFY2025
- RevenueUSD 0
- Revenue growth-100.0%
- Net income-USD 14.40M
- Free cash flow-USD 9.25M
Valuation Snapshot
latest market cap is EUR 50.38M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 14.40M | -USD 9.25M | n/a | -0.15 | USD 13.52M | USD 9.31M | -USD 9.91M |
| FY2024 | USD 1.78M | -USD 51.38M | -USD 19.84M | 67.4% | -0.66 | USD 11.77M | USD 8.06M | -USD 1.68M |
| FY2023 | USD 0 | -USD 78.69M | -USD 72.03M | n/a | -1.03 | USD 23.88M | USD 8.85M | USD 40.20M |
| FY2022 | USD 0 | -USD 88.30M | -USD 107.54M | n/a | -1.16 | USD 105.23M | USD 10.76M | USD 122.01M |
| FY2021 | USD 0 | -USD 213.07M | -USD 62.85M | n/a | -14.3 | USD 211.99M | USD 7.04M | USD 211.62M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-15 | EUR 50.38M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Sirnaomics Ltd.
Sirnaomics Ltd., an RNA therapeutics biopharmaceutical company, discovers and develops drugs for indications with medical needs in the People's Republic of China. The company's therapeutics products focus on oncology and fibrosis, anticoagulant therapies, cardiometabolic disease, complement-mediated diseases, medical aesthetics, and viral infections. Its lead drug candidates comprising STP705 for the treatment of non-melanoma skin cancer and for focal fat reduction; STP369 to treat head and neck cancer;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Sirnaomics Ltd.'s market cap?
Sirnaomics Ltd.'s market capitalization is EUR 50.38M.
What does Sirnaomics Ltd. do?
Sirnaomics Ltd., an RNA therapeutics biopharmaceutical company, discovers and develops drugs for indications with medical needs in the People's Republic of China. The company's therapeutics products focus on oncology and fibrosis, anticoagulant therapies, cardiometabolic disease, complement-mediated diseases, medical aesthetics, and viral infections. Its lead drug candidates comprising STP705 for the treatment of non-melanoma skin cancer and for focal fat reduction; STP369 to treat head and neck cancer; and STP707 and STP355 to treat solid tumors.